Results 21 to 30 of about 333,256 (300)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

OncoImmunology, 2020
The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified.
Bryan Oronsky, Corey A. Carter, Scott Caroen, Curtis Scribner, Arnold Oronsky, Tony R. Reid   +5 more
doaj   +1 more source

Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis [PDF]

, 2004
Background Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes.
Abouna, Sylvie, Cheung, Linda, Zervou, Sevasti I., Khan, Michael, Stella Pelengaris, Sylvie Abouna, Sevasti Zervou, Michael Khan, Linda Cheung, Ifandi, Vasiliki, Pelengaris, Stella, Vasiliki Ifandi   +11 more
core   +1 more source

Physiological roles of the oncoprotein c-Myc in mouse mammary gland development [PDF]

, 2009
c-Myc, a transcription factor that affects a large number of target genes, is one of the most frequently deregulated oncoproteins in human cancer. The wide-ranging biological functions of c-Myc include regulation of the cell cycle, differentiation ...
Stölzle, Tina
core   +1 more source

Cooperative STAT/NF-κB signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression

Nature Communications, 2018
Metabolic rewiring of cancer cells can be driven by both extrinsic and intrinsic factors. Here the authors show that microenvironmental factors induce metabolic rewiring of B-cell lymphoma through activation of STAT3 and NF-ΚB resulting in upregulation ...
Maren Feist, Philipp Schwarzfischer, Paul Heinrich, Xueni Sun, Judith Kemper, Frederike von Bonin, Paula Perez-Rubio, Franziska Taruttis, Thorsten Rehberg, Katja Dettmer, Wolfram Gronwald, Jörg Reinders, Julia C. Engelmann, Jan Dudek, Wolfram Klapper, Lorenz Trümper, Rainer Spang, Peter J. Oefner, Dieter Kube   +18 more
doaj   +1 more source

Involvement of Myc targets in c-myc and N-myc induced human tumors [PDF]

Oncogene, 1998
The myc proto-oncogenes are transcription factors that directly regulate the expression of other genes, by binding to the specific DNA sequence, CACGTG. Among the target genes for c-Myc regulation are ECA39, p53, ornithine decarboxylase (ODC), alpha-prothymosin and Cdc25A.
T, Ben-Yosef, O, Yanuka, D, Halle, N, Benvenisty   +3 more
openaire   +2 more sources

Deciphering c-MYC-regulated genes in two distinct tissues [PDF]

, 2011
Background: The transcription factor MYC is a critical regulator of diverse cellular processes, including both replication and apoptosis. Differences in MYC-regulated gene expression responsible for such opposing outcomes in vivo remain obscure.
Lesley Ward, Heather Turner, Michael Khan, Ward, Lesley (Lesley A.), Brown, Helen, Turner, Heather, Helen Brown, Hunter, Ewan, Ward, Lesley, Khan, Michael, Samuel C Robson, Stella Pelengaris, Brown, Helen (Helen E.), Robson, Samuel C, Robson, Samuel Charles, Pelengaris, Stella, Ewan Hunter   +16 more
core   +1 more source

Targeting MYC through WDR5

Molecular & Cellular Oncology, 2020
The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated – but currently undruggable – anti-cancer target.
Lance R. Thomas, Clare M. Adams, Stephen W. Fesik, Christine M. Eischen, William P. Tansey   +4 more
doaj   +1 more source

Plasmablastic Lymphoma in HIV-Positive Patients: A Literature Review and Results of a Russian Multi-Center Retrospective Study

Клиническая онкогематология, 2022
Background. Plasmablastic lymphoma (PBL) is a rare lymphoproliferative disease which is almost exclusively associated with immunodeficiency. Most ample experience of chemotherapy and hematopoietic stem cells transplantation (HSCT) in this lymphoma ...
Marina Olegovna Popova, I. V. Tsygankov, Ya. V. Gudozhnikova, Yu. A. Rogacheva, N. P. Volkov, K. V. Lepik, M. V. Demchenkova, M. V. Grigoreva, A. Yu. Efirkina, T. V. Shneider, Yu. V. Kopeikina, S. A. Stepanova, V. G. Potapenko, A. V. Klimovich, N. V. Medvedeva, M. A. Kolesnikova, T. I. Pospelova, N. B. Mikhailova, V. V. Baikov, A. D. Kulagin   +19 more
doaj   +1 more source

Targeting of the MYCN protein with small molecule c-MYC inhibitors [PDF]

, 2014
This study was funded by grants from the Swedish Research Council and the Swedish Cancer Society. IM and HZ were recipients of graduate student grants from KI (KID), MAH was recipient of a Senior Investigator Award from the Swedish Cancer Society, and ...
Edward V Prochownik, Inga Müller, Oliynyk, G, Ganna Oliynyk (568258), Zirath Hanna, Prochownik Edward V., Larsson, Karin, Anna Frenzel, Marie Arsenian Henriksson, Anna Frenzel (194997), Edward V. Prochownik (163628), Henriksson, MA, Westwood Nicholas J., Oliynyk, Ganna, Hanna Zirath, Marie Arsenian Henriksson (195006), Oliynyk Ganna, Ganna Oliynyk, Larsson, K, Frenzel, A, Frenzel, Anna, Zirath, Hanna, Prochownik, Edward V., Nicholas J Westwood, Frenzel Anna, Zirath, H, Henriksson Marie Arsenian, Karin Larsson, Muller, Inga, Nicholas J. Westwood, Inga Müller (568256), Nicholas J. Westwood (254891), Edward V. Prochownik, Müller, I, Westwood, NJ, Müller Inga, Henriksson, Marie Arsenian, Karin Larsson (568257), Hanna Zirath (195000), Prochownik, EV, Westwood, Nicholas J., Larsson Karin   +41 more
core   +1 more source

MYC/NBS1-Mediated DNA Damage Response is Involved in the Inhibitory Effect of Hydroxysafflor Yellow A on Glioma Cells

Drug Design, Development and Therapy, 2021
Dongfang Tang,1 Tao Huang,2 Qilong Tian,2 Julei Wang2 1Department of Neurosurgery, Henan Provincial People’s Hospital, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China ...
Tang D, Huang T, Tian Q, Wang J
doaj